Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 24 articles: HTML format

Single Articles

August 2022
1. BOULEAU A, Nozach H, Dubois S, Kereselidze D, et al
   Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of (89)Zr-Labeled Anti-PD-L1 Antibody Formats.
   J Nucl Med. 2022;63:1259-1265.
   PubMed     Abstract available
   
   
   June 2022
2. STERBIS E, Liang R, Trivedi P, Kwak J, et al
   Lack of adherence to guideline-based imaging prior to subsequent radiation in patients with non-small cell lung cancer: Impact on patient outcomes.
   J Nucl Med. 2022 Jun 9. pii: jnumed.122.264131. doi: 10.2967/jnumed.122.264131.
   PubMed     Abstract available
   
   
   April 2022
3. KUNIHIRO AG, Sarrett SM, Lastwika KJ, Solan JL, et al
   CD133 as a Biomarker for an Autoantibody-to-ImmunoPET Paradigm for the Early Detection of Small Cell Lung Cancer.
   J Nucl Med. 2022 Apr 28. pii: jnumed.121.263511. doi: 10.2967/jnumed.121.263511.
   PubMed     Abstract available
   
   
   March 2022
4. YUSUFALY TI, Mell LK
   Reply: Adding Nontumor Radiomic Features to the Prognostic Model Is Bothersome but Useful.
   J Nucl Med. 2022;63:495.
   PubMed    
   
   
   
5. ZHANG L, Zhang B
   Adding Nontumor Radiomic Features to the Prognostic Model Is Bothersome but Useful.
   J Nucl Med. 2022;63:494-495.
   PubMed    
   
   
   February 2022
6. ZIDAN L, Iravani A, Oleinikov K, Ben-Haim S, et al
   Efficacy and Safety of (177)Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study.
   J Nucl Med. 2022;63:218-225.
   PubMed     Abstract available
   
   
   December 2021
7. KOLINGER GD, Vallez Garcia D, Kramer GM, Frings V, et al
   Effects of tracer uptake time in non-small cell lung cancer (18)F-FDG PET radiomics.
   J Nucl Med. 2021 Dec 21. pii: jnumed.121.262660. doi: 10.2967/jnumed.121.262660.
   PubMed     Abstract available
   
   
   August 2021
8. FARWELL MD, Gamache RF, Babazada H, Hellmann MD, et al
   CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of (89)Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
   J Nucl Med. 2021 Aug 19. pii: jnumed.121.262485. doi: 10.2967/jnumed.121.262485.
   PubMed     Abstract available
   
   
   
9. SMIT J, Borm FJ, Niemeijer AN, Huisman MC, et al
   PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
   J Nucl Med. 2021 Aug 12. pii: jnumed.121.262473. doi: 10.2967/jnumed.121.262473.
   PubMed     Abstract available
   
   
   July 2021
10. ZHOU X, Jiang J, Yang X, Liu T, et al
    First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262045. doi: 10.2967/jnumed.121.262045.
    PubMed     Abstract available
    
    
    
11. ROHRICH M, Leitz D, Glatting FM, Wefers AK, et al
    Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261925. doi: 10.2967/jnumed.121.261925.
    PubMed     Abstract available
    
    
    
12. NIEMEIJER AN, Oprea Lager DE, Huisman MC, Hoekstra OS, et al
    First-in-human study of (89)Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261926. doi: 10.2967/jnumed.121.261926.
    PubMed     Abstract available
    
    
    May 2021
13. GUBERINA M, Poettgen C, Metzenmacher M, Wiesweg M, et al
    PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.
    J Nucl Med. 2021 May 20. pii: jnumed.120.260646. doi: 10.2967/jnumed.120.260646.
    PubMed     Abstract available
    
    
    January 2021
14. LAFFON E, Marthan R
    Distribution Volume of (18)F-BMS-986192 in NSCLC Patients.
    J Nucl Med. 2021;62:144.
    PubMed    
    
    
    December 2020
15. STUSCHKE M, Pottgen C
    (18)F-FDG PET/CT for Target Volume Contouring in Lung Cancer Radiotherapy.
    J Nucl Med. 2020;61.
    PubMed    
    
    
    November 2020
16. AYATI N, Lee ST, Zakavi SR, Cheng M, et al
    Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods.
    J Nucl Med. 2020 Nov 27. pii: jnumed.120.254508. doi: 10.2967/jnumed.120.254508.
    PubMed     Abstract available
    
    
    October 2020
17. CHRISTENSEN TN, Langer SW, Persson GF, Larsen KR, et al
    (18)F-FLT-PET/CT adds value to (18)F-FDG-PET/CT for diagnosing relapse after definitive radiotherapy in patients with lung cancer. Results of a prospective clinical trial.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.247742. doi: 10.2967/jnumed.120.247742.
    PubMed     Abstract available
    
    
    September 2020
18. GALLDIKS N, Abdulla DS, Scheffler M, Wolpert F, et al
    Treatment Monitoring of Immunotherapy and Targeted Therapy using (18)F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences.
    J Nucl Med. 2020 Sep 4. pii: jnumed.120.248278. doi: 10.2967/jnumed.120.248278.
    PubMed     Abstract available
    
    
    
19. CASTELLO A, Lopci E
    Reply: Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using (18)F-FDG PET/CT.
    J Nucl Med. 2020;61:1405.
    PubMed    
    
    
    June 2020
20. GIESEL F, Adeberg S, Syed M, Lindner T, et al
    FAPI-74 PET/CT Using Either (18)F-AlF or Cold-kit (68)Ga-labeling: Biodistribution, Radiation Dosimetry and Tumor Delineation in Lung Cancer Patients.
    J Nucl Med. 2020 Jun 26. pii: jnumed.120.245084. doi: 10.2967/jnumed.120.245084.
    PubMed     Abstract available
    
    
    
21. FERDINANDUS J, Barbato F, Chodyla M, Fendler WP, et al
    Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma.
    J Nucl Med. 2020 Jun 12. pii: jnumed.120.245803. doi: 10.2967/jnumed.120.245803.
    PubMed     Abstract available
    
    
    April 2020
22. REYNOLDS JC, Maass-Moreno R, Thomas A, Ling A, et al
    FDG-PET assessment of malignant pleural mesothelioma: Total Lesion volume and Total Lesion Glycolysis; the central role of volume.
    J Nucl Med. 2020 Apr 13. pii: jnumed.119.238733. doi: 10.2967/jnumed.119.238733.
    PubMed     Abstract available
    
    
    February 2020
23. SEBAN RD, Schwartz LH, Bonardel G, Dercle L, et al
    Diagnosis of Hyper-progressive Disease in Patients Treated with Checkpoint Inhibitors using (18)F-FDG PET/CT.
    J Nucl Med. 2020 Feb 21. pii: jnumed.120.242768. doi: 10.2967/jnumed.120.242768.
    PubMed    
    
    
    June 2019
24. JREIGE M, Dunet V, Letovanec I, Prior JO, et al
    Pulmonary lymphangitic carcinomatosis: diagnostic performance of HRCT and (18)F-FDG-PET/CT in correlation to clinical pathologic outcome.
    J Nucl Med. 2019 Jun 21. pii: jnumed.119.229575. doi: 10.2967/jnumed.119.229575.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: